SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (115)3/3/1999 1:11:00 AM
From: Larry Liebman  Read Replies (1) | Respond to of 1834
 
From what I read, the DHEA program was a l-o-n-g shot( and I assume most analysts had a similar prediction/predilection). The collaboration announced today(on the order of $78 million) is slightly less than the market cap of $97 million. With $66 million in cash, the tech value is $30 million with a company with 4(?) molecules in the clinic. Perhaps this is soon to be munchable!!!



To: LLCF who wrote (115)3/3/1999 7:18:00 AM
From: Laurens  Read Replies (1) | Respond to of 1834
 
On balance, I think the AHP deal
will overshadow the negative news.
I worked 17 years for Wyeth, and
I am very pleased they are going to work with NBIX.
AHP are not likely to start something
if there is not a pretty good chance of
getting to a marketable product.
Good news indeed!
Should put NBIX stock up at least $ 1.-
(AHP also has deal with LIPO. The latter stock has been doing great over
the past year)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News